BCL2 and diffuse large B-cell lymphoma: CPI203 has previously been shown to downregulate BCL2A1 expression in a small-molecule antagonist of BCL-2 (ABT-199) drug-resistant diffuse large B-cell lymphoma (DLBCL)19.